Toxicity patterns with immunomodulating antibodies and their combinations
- PMID: 25965360
- DOI: 10.1053/j.seminoncol.2015.02.011
Toxicity patterns with immunomodulating antibodies and their combinations
Abstract
Immune checkpoint molecules cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1), but also LAG-3 and TIM-3, are involved in regulation of peripheral tolerance in order to prevent autoimmunity. Blocking of these cell surface proteins by antibodies has resulted in remarkable anti-tumor immunity; however this immunity is accompanied by immune-related adverse reactions (irAEs), resembling autoimmune diseases. Hence, treatment with immunosuppressive drugs is highly effective and resolves the symptoms caused by these adverse events rapidly. In this review, toxicity patterns observed with immune checkpoint blockade are described for single-agent and combination treatments.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations.Semin Oncol. 2015 Jun;42(3):363-77. doi: 10.1053/j.seminoncol.2015.02.015. Epub 2015 Feb 16. Semin Oncol. 2015. PMID: 25965355 Review.
-
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?Eur J Cancer. 2019 Nov;122:72-90. doi: 10.1016/j.ejca.2019.07.014. Epub 2019 Oct 18. Eur J Cancer. 2019. PMID: 31634647 Review.
-
Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.Clin Cancer Res. 2016 Sep 15;22(18):4550-5. doi: 10.1158/1078-0432.CCR-15-2569. Epub 2016 Jul 19. Clin Cancer Res. 2016. PMID: 27435397 Review.
-
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24. J Immunol. 2015. PMID: 25539810 Free PMC article.
-
Auto-immunité et gestion des toxicités des traitements par anti-check point inhibiteurs.Bull Cancer. 2016 Nov;103 Suppl 1:S175-S185. doi: 10.1016/S0007-4551(16)30376-9. Bull Cancer. 2016. PMID: 28057182 French.
Cited by
-
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer.Clin Transl Immunology. 2016 Apr 15;5(4):e70. doi: 10.1038/cti.2016.16. eCollection 2016 Apr. Clin Transl Immunology. 2016. PMID: 27195113 Free PMC article.
-
A Therapy-Terminating Event: Programmed Death-1 Inhibitor-Induced Mucositis.Cureus. 2022 Sep 20;14(9):e29377. doi: 10.7759/cureus.29377. eCollection 2022 Sep. Cureus. 2022. PMID: 36304369 Free PMC article.
-
Self-Organizing Map-Based Assessment of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.Cureus. 2025 Jan 2;17(1):e76813. doi: 10.7759/cureus.76813. eCollection 2025 Jan. Cureus. 2025. PMID: 39902026 Free PMC article.
-
The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials.Onco Targets Ther. 2016 Sep 23;9:5867-5874. doi: 10.2147/OTT.S115262. eCollection 2016. Onco Targets Ther. 2016. PMID: 27713640 Free PMC article.
-
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.J Immunother Cancer. 2016 Dec 20;4:89. doi: 10.1186/s40425-016-0196-z. eCollection 2016. J Immunother Cancer. 2016. PMID: 28031819 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials